- Corporate Officers - S
- Sohn Catherine A.
Insider Trading History of Sohn Catherine A.
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sohn Catherine A. since 2013.
This trader's CIK number is 1555132.
At the time of last reporting, Sohn Catherine A. was the Director of Jazz Pharmaceuticals Plc. (stock ticker symbol JAZZ).
Also see all insider trading activities at Jazz Pharmaceuticals Plc.
Note that in the past
Sohn Catherine A. also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Axcella Health Inc. (AXLA) by Sohn Catherine A.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | AXLA | 1,000 | $4,870 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Lifecore Biomedical, Inc. \de\ (LNDC) by Sohn Catherine A.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | LNDC | 1,000 | $11,230 | 0 | $0 | 14,240 | $132,118 |
| 2018 | LNDC | 0 | $0 | 0 | $0 | 4,286 | $58,503 |
| 2017 | LNDC | 0 | $0 | 0 | $0 | 5,282 | $71,307 |
| 2016 | LNDC | 0 | $0 | 0 | $0 | 3,475 | $39,823 |
| 2015 | LNDC | 0 | $0 | 0 | $0 | 7,552 | $100,051 |
| 2014 | LNDC | 0 | $0 | 0 | $0 | 3,496 | $40,273 |
Yearly summary of insider trading at Rubius Therapeutics, Inc. (RUBY) by Sohn Catherine A.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | RUBY | 2,500 | $57,500 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Jazz Pharmaceuticals Plc (JAZZ) by Sohn Catherine A.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | JAZZ | 0 | $0 | 1,241 | $171,455 | 0 | $0 |
| 2022 | JAZZ | 0 | $0 | 1,089 | $165,879 | 0 | $0 |
| 2021 | JAZZ | 0 | $0 | 1,306 | $193,235 | 0 | $0 |
| 2020 | JAZZ | 0 | $0 | 13,431 | $2,042,185 | 12,500 | $803,687 |
| 2019 | JAZZ | 0 | $0 | 726 | $98,481 | 0 | $0 |
| 2018 | JAZZ | 0 | $0 | 660 | $116,563 | 0 | $0 |
| 2017 | JAZZ | 0 | $0 | 662 | $94,857 | 0 | $0 |
| 2016 | JAZZ | 0 | $0 | 633 | $86,372 | 0 | $0 |
| 2015 | JAZZ | 0 | $0 | 1,455 | $262,056 | 0 | $0 |
| 2014 | JAZZ | 0 | $0 | 1,731 | $230,482 | 0 | $0 |
| 2013 | JAZZ | 0 | $0 | 640 | $51,852 | 0 | $0 |
Insider trading activities at 4 companies by Sohn Catherine A.:
1. Axcella Health Inc. (AXLA)
2. Lifecore Biomedical, Inc. \de\ (LNDC)
3. Rubius Therapeutics, Inc. (RUBY)
4. Jazz Pharmaceuticals Plc (JAZZ)
Table 1. Insider trading of Axcella Health Inc. (AXLA) by Sohn Catherine A.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-01-17 | AXLA | Buy | 1,000 | 4.87 | 4,870 |
Table 2. Insider trading of Lifecore Biomedical, Inc. \de\ (LNDC) by Sohn Catherine A.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-10-04 | LNDC | Option Ex | 10,000 | 9.01 | 90,100 |
| 2019-05-30 | LNDC | Option Ex | 4,240 | 9.91 | 42,018 |
| 2019-01-10 | LNDC | Buy | 1,000 | 11.23 | 11,230 |
| 2018-05-23 | LNDC | Option Ex | 4,286 | 13.65 | 58,503 |
| 2017-05-25 | LNDC | Option Ex | 5,282 | 13.50 | 71,307 |
| 2016-05-28 | LNDC | Option Ex | 3,475 | 11.46 | 39,823 |
| 2015-11-23 | LNDC | Option Ex | 3,333 | 11.93 | 39,762 |
| 2015-05-29 | LNDC | Option Ex | 4,219 | 14.29 | 60,289 |
| 2014-06-06 | LNDC | Option Ex | 3,496 | 11.52 | 40,273 |
Table 3. Insider trading of Rubius Therapeutics, Inc. (RUBY) by Sohn Catherine A.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-07-20 | RUBY | Buy | 2,500 | 23.00 | 57,500 |
Table 4. Insider trading of Jazz Pharmaceuticals Plc (JAZZ) by Sohn Catherine A.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-08-14 | JAZZ | Sale | 1,241 | 138.16 | 171,455 |
| 2022-08-08 | JAZZ | Sale | 1,089 | 152.32 | 165,879 |
| 2021-08-06 | JAZZ | Sale | 1,306 | 147.96 | 193,235 |
| 2020-11-04 | JAZZ | Option Ex | 12,500 | 64.30 | 803,687 |
| 2020-11-04 | JAZZ | Sale | 12,500 | 154.00 | 1,925,000 |
| 2020-08-07 | JAZZ | Sale | 931 | 125.87 | 117,185 |
| 2019-08-09 | JAZZ | Sale | 726 | 135.65 | 98,481 |
| 2018-08-10 | JAZZ | Sale | 660 | 176.61 | 116,563 |
| 2017-08-11 | JAZZ | Sale | 662 | 143.29 | 94,857 |
| 2016-08-15 | JAZZ | Sale | 633 | 136.45 | 86,372 |
| 2015-08-11 | JAZZ | Sale | 654 | 177.77 | 116,258 |
| 2015-08-10 | JAZZ | Sale | 801 | 182.02 | 145,798 |
| 2014-08-12 | JAZZ | Sale | 1,731 | 133.15 | 230,482 |
| 2013-08-14 | JAZZ | Sale | 640 | 81.02 | 51,852 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Sohn Catherine A.
(Director of Jazz Pharmaceuticals Plc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.